Clinicopathologic Correlates of PIT1 and SF1-Multilineage Pituitary Neuroendocrine Tumors and the Diagnostic Utility of NKX2.2 Immunohistochemistry in Pituitary Pathology
- PMID: 38649148
- DOI: 10.5858/arpa.2023-0543-OA
Clinicopathologic Correlates of PIT1 and SF1-Multilineage Pituitary Neuroendocrine Tumors and the Diagnostic Utility of NKX2.2 Immunohistochemistry in Pituitary Pathology
Abstract
Context.—: PIT1 and SF1-multilineage pituitary neuroendocrine tumors (PitNETs) have been defined since the classification of adenohypophysial tumors based on the PIT1, SF1, and TPIT transcription factors.
Objective.—: To describe the clinicopathologic features of PIT1 and SF1-multilineage PitNETs and to contribute to the pituitary pathology practice by questioning the expression of NKX2.2 in PitNETs.
Design.—: We reviewed 345 PitNETs and described the clinicopathologic features of 8 PIT1 and SF1-multilineage tumors. NKX2.2 positivity and staining pattern were compared to those of 45 PitNETs from the control group.
Results.—: PIT1 and SF1-multilineage PitNET patients had a mean age of 41.13 (range, 14-58 years) and a mean tumor diameter of 14.0 mm (range, 8-20 mm). The most common clinical presentation was acromegaly (6 of 8), and postoperative remission was achieved in all patients. On histomorphologic examination, a pseudopapillary pattern was seen in 5 of the tumors, either focally or diffusely. In addition to PIT1 and SF1, there was a diffuse staining with growth hormone and a predominantly perinuclear staining with cytokeratin 18. With NKX2.2, all multilineage tumors were positive, of which 5 were diffuse and 3 were focal. In the control group, 8 tumors (8 of 45) were positive, of which only 1 was diffuse and 7 were focal.
Conclusions.—: In conclusion, NKX2.2 is a transcription factor that can be used as an additional tool in pituitary pathology, and PIT1 and SF1-multilineage PitNETs are specific tumors that usually present with acromegaly, show signs of a nonaggressive clinical course, have a pseudopapillary histomorphology, and express NKX2.2.
© 2025 College of American Pathologists.
Conflict of interest statement
The authors have no relevant financial interest in the products or companies described in this article.
Similar articles
-
Multilineage Pituitary Neuroendocrine Tumors Expressing TPIT and SF1: A Clinicopathological Series of Six Tumors.Endocr Pathol. 2024 Dec;35(4):349-353. doi: 10.1007/s12022-024-09841-0. Epub 2024 Nov 23. Endocr Pathol. 2024. PMID: 39579326
-
A contemporary, multiinstitutional analysis of transcription factor lineage in pituitary adenomas: comparative study of neuroimaging, histopathology, and clinical outcomes.J Neurosurg. 2025 Mar 14;143(1):146-154. doi: 10.3171/2024.10.JNS24853. Print 2025 Jul 1. J Neurosurg. 2025. PMID: 40085941
-
Multilineage Pituitary Neuroendocrine Tumors (PitNETs) Expressing PIT1 and SF1.Endocr Pathol. 2023 Sep;34(3):273-278. doi: 10.1007/s12022-023-09777-x. Epub 2023 Jun 2. Endocr Pathol. 2023. PMID: 37268858
-
Clinical and Radiographic Presentation and Surgical Outcomes of T-Box Pituitary Transcription Factor (TPIT) Silent Corticotroph Pituitary Neuroendocrine Tumors: A Multi-institutional Experience and Review of the Literature.World Neurosurg. 2025 Apr;196:123791. doi: 10.1016/j.wneu.2025.123791. Epub 2025 Mar 18. World Neurosurg. 2025. PMID: 39952399 Review.
-
Pituitary Apoplexy in a Non-Functioning PitNET After Cabergoline Use: Case Report and Review of the Literature.J Clin Med. 2025 Jul 17;14(14):5089. doi: 10.3390/jcm14145089. J Clin Med. 2025. PMID: 40725781 Free PMC article. Review.
Cited by
-
PIT-1/SF-1-positive pituitary tumors in patients with acromegaly: transcriptomic perspective.Acta Neuropathol Commun. 2025 Aug 14;13(1):174. doi: 10.1186/s40478-025-02091-z. Acta Neuropathol Commun. 2025. PMID: 40813692 Free PMC article.
-
An Old New Friend: Folliculo-Stellate Cells in Pituitary Neuroendocrine Tumors.Cells. 2025 Jul 3;14(13):1019. doi: 10.3390/cells14131019. Cells. 2025. PMID: 40643539 Free PMC article.
-
Comparison of the clinical and prognostic characteristics of patients with different pathological types in acromegaly.Front Endocrinol (Lausanne). 2025 May 12;16:1571598. doi: 10.3389/fendo.2025.1571598. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 40421250 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical